Industry
CKD Bio Corporation
Total Trials
5
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 1
3(60.0%)
Phase 3
1(20.0%)
N/A
1(20.0%)
5Total
Phase 1(3)
Phase 3(1)
N/A(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT07496021Not ApplicableRecruiting
Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Role: lead
NCT05804656Phase 3Completed
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
Role: lead
NCT05382767Phase 1Completed
Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity
Role: lead
NCT05292638Phase 1Completed
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
Role: lead
NCT05428930Phase 1Completed
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
Role: lead
All 5 trials loaded